- Citations, last 5 years
- 221
- Works, last 5 years
- 110
- h-index
- 18
- Scientists listed
- 9
- Grants since 2016
- 18
Grants received
2025–2027 · research · R44
Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation
Matthew Dominic Bacchetta · Xylem (United States) · funded by National Institutes of Health
2024–2025 · research · R43
Development of a safe and effective topically administered pharmacotherapy to treat acute corneal pain
Tung Fong · Xylem (United States) · funded by National Institutes of Health
2024–2025 · research · R44
Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2024–2027 · research · R44
Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2024–2027 · research · R44
Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2024–2027 · research · R44
Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Combined Pro-Plasticity Reprogramming Strategies to Enhance Post-Infarction Myocardial Recovery
Henricus Duckers · Xylem (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2021–2022 · research · R44
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2020–2021 · research · R43
Biomimetic lung sealant to rapidly heal pulmonary air leaks, decrease recovery time, and reduce associated costs to the healthcare system,
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2020–2024 · cooperative agreement · Cooperative Agreement
SBIR Phase II: An Economic Optical Fiber Solution to the Last Mile Problem
Phillip Turner · Xylem (United States) · funded by National Science Foundation
2018–2020 · research · R43
Native cell specific microenvironments for improved cell culture
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Fibrotic lung extracellular matrix cell culture substrate to improve predictive in vitro models of pulmonary fibrosis for accelerating drug development towards more effective treatment options
John David O'Neill · Xylem (United States) · funded by National Institutes of Health
2018–2019 · grant · Standard Grant
SBIR Phase I: An Economic Optical Fiber Solution to the Last Mile Problem
Phillip Turner · Xylem (United States) · funded by National Science Foundation
2016–2020 · grant · Standard Grant
SBIR Phase II: Novel Bioprocess for Lipid Production from Industrial Byproducts
Thomas Jeffries · Xylem (United States) · funded by National Science Foundation